Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
NCT ID: NCT00046800
Last Updated: 2011-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
80 participants
INTERVENTIONAL
2002-09-30
2003-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OSI-211 (Liposomal Lurtotecan)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm on spiral CT scan).
* One or two prior regimens of chemotherapy. At least one regimen must have contained cisplatin or carboplatin.
* At least three weeks since prior chemotherapy and recovery from any related toxicities.
* At least four weeks since prior radiotherapy and recovery from any related toxicities.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OSI Pharmaceuticals
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NYU- Kaplan Comprehensive Cancer Center
New York, New York, United States
The Sarah Cannon Cancer Center, Centennial Medical Center
Nashville, Tennessee, United States
St Chad's Unit
Birmingham, , United Kingdom
Beatson Oncology Centre
Glasgow, , United Kingdom
Royal Surrey County Hospital
Guildford, Surrey, , United Kingdom
Royal Marsden NHS Trust
London, , United Kingdom
Northern Centre for Cancer Research, Newcastle General Hospital
Newcastle upon Tyne, , United Kingdom
Mount Vernon Hospital
Northwood, Middlesex, , United Kingdom
CRC Department of Medical Oncology
Sutton Surrey, , United Kingdom
Taunton & Somerset Hospital
Taunton, , United Kingdom
Medical Oncology Unit, Torbay District General Hospital
Torquay, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
110-20
Identifier Type: -
Identifier Source: org_study_id